title: Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols.
abstract: Alzheimer's disease and Parkinson's disease are neurodegenerative disorders characterised by the misfolding of proteins into soluble prefibrillar aggregates. These aggregate complexes disrupt mitochondrial function, initiating a pathophysiological cascade leading to synaptic and neuronal degeneration. In order to explore the interaction of amyloid aggregates with mitochondrial membranes, we made use of two in vitro model systems, namely: (i) lipid vesicles with defined membrane compositions that mimic those of mitochondrial membranes, and (ii) respiring mitochondria isolated from neuronal SH-SY5Y cells. External application of soluble prefibrillar forms, but not monomers, of amyloid-beta (Aβ42 peptide), wild-type α-synuclein (α-syn), mutant α-syn (A30P and A53T) and tau-441 proteins induced a robust permeabilisation of mitochondrial-like vesicles, and triggered cytochrome c release (CCR) from isolated mitochondrial organelles. Importantly, the effect on mitochondria was shown to be dependent upon cardiolipin, an anionic phospholipid unique to mitochondria and a well-known key player in mitochondrial apoptosis. Pharmacological modulators of mitochondrial ion channels failed to inhibit CCR. Thus, we propose a generic mechanism of thrilling mitochondria in which soluble amyloid aggregates have the intrinsic capacity to permeabilise mitochondrial membranes, without the need of any other protein. Finally, six small-molecule compounds and black tea extract were tested for their ability to inhibit permeation of mitochondrial membranes by Aβ42, α-syn and tau aggregate complexes. We found that black tea extract and rosmarinic acid were the most potent mito-protectants, and may thus represent important drug leads to alleviate mitochondrial dysfunction in neurodegenerative diseases.
authors.affiliation: Department of Physiology and Biochemistry, University of Malta, Msida, Malta.
authors.forename: Angelique
authors.initials: A
authors.lastname: Camilleri
authors.forename: Claire
authors.initials: C
authors.lastname: Zarb
authors.forename: Mario
authors.initials: M
authors.lastname: Caruana
authors.forename: Ulrike
authors.initials: U
authors.lastname: Ostermeier
authors.forename: Stephanie
authors.initials: S
authors.lastname: Ghio
authors.forename: Tobias
authors.initials: T
authors.lastname: Högen
authors.forename: Felix
authors.initials: F
authors.lastname: Schmidt
authors.forename: Armin
authors.initials: A
authors.lastname: Giese
authors.forename: Neville
authors.initials: N
authors.lastname: Vassallo
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism*; D045744:Cell Line, Tumor; D006801:Humans; D051336:Mitochondrial Membranes / Q000187:drug effects / Q000378:metabolism*; D010539:Permeability; D059808:Polyphenols / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000378:metabolism; D051844:alpha-Synuclein / Q000378:metabolism; D016875:tau Proteins / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D059808:Polyphenols; D011994:Recombinant Proteins; D051844:alpha-Synuclein; D016875:tau Proteins
keywords: AD; Alpha-synuclein; Alzheimer's disease; Amyloid-beta; Aβ(42); CCR; CL; Cardiolipin; Cyto c; IM and IMM; Mitochondrial membrane; OGB-1; OM and OMM; Oregon Green® 488 BAPTA-1; PD; Parkinson's disease; Polyphenol; TX-100; Tau; Triton X-100; WT; amyloid-beta (1–42); cardiolipin; cytochrome c; cytochrome c release; inner mitochondrial membrane; outer mitochondrial membrane; wild-type; α-syn; α-synuclein